ASLAN Pharmaceuticals Limited (ASLN)
Upgrades & Downgrades
Latest ASLN news
ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis
ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic d...
Zacks Investment Research
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with mo...
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022
MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biophar...
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading G...
MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biophar...
ASLN Stock: Why It Fell Over 25% Today
The stock price of Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) fell by over 25%. This is why it happened.
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has announced topline data from its Phase 1 study of ASLAN004 for moderate-to-severe atopic dermatitis (AD). ...
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN00...
- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Exp...
MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopha...
Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options
Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.